Ongoing Medical Trials
Trial 1:
Official Title: Effects of the Thyroid Hormone Analog Triac on the Neurocognitive Phenotype in Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial II
Description: The current Trial (Triac Trial II) will investigate if Triac treatment in AHDS patients improves the neurocognitive phenotype.
Primary Purpose: Treatment
Estimated Study Start Date : June 2018
Estimated Study Completion Date : December 2022
Location: Erasmus Medical Center, Rotterdam
Principal Investigator: Dr. W.E. Wisser, Erasmus Medical Center
Recruitment Status : Now recruiting
Web page: https://clinicaltrials.gov/ct2/show/NCT02396459
Trial 2:
Name of the trial: Rescue of Infants With Mct8 Deficiency Under Emergency Use Single Patient Expanded Access Treatment
Description: MCT8 deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement.
Location: University of Miami, Miller School of Medicine, United States, Florida
Principal Investigator: Roy E Weiss, M.D.
Drug: Diiodothyropropionic acid (DITPA)
Web page: https://clinicaltrials.gov/ct2/show/NCT04143295
Past Clinical Trials
Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial.
Description:
The current trial will investigate if Triac treatment in AHDS patients:
1. reduces the toxic effects of the high T3 levels
2. restores the local TH deficiency in brain.
Primary Purpose: Treatment
Study Start Date: Oct 2014
Estimated completion date: May 2018
Location: Erasmus Medical Center, Rotterdam
Principal Investigator: Dr. W.E. Wisser, Erasmus Medical Center
Recruitment Status : Active, not recruiting
Web page: https://clinicaltrials.gov/ct2/show/NCT02060474